Due to respiration, many tumours in the thorax and abdomen may move as much as 3 cm peak-to-peak during radiation treatment. To mitigate motion-induced irradiation of normal lung tissue, clinics have employed external markers to gate the treatment beam. This technique assumes that the correlation between the external surface and the internal tumour position remains constant interfractionally and intra-fractionally. In this work, a study has been performed to assess the validity of this correlation assumption for external surface based gated radiotherapy, by measuring the residual tumour motion within a gating window. Eight lung patients with implanted fiducial markers were studied at the NTT Hospital in Sapporo, Japan. Synchronized internal marker positions and external abdominal surface positions were measured during the entire course of treatment. Stereoscopic imaging was used to find the internal markers in four dimensions. The data were used retrospectively to assess conventional external surrogate respiratory-gated treatment. Both amplitude-and phase-based gating methods were investigated. For each method, three gating windows were investigated, each giving 40%, 30% and 20% duty cycle, respectively. The residual motion of the internal marker within these six gating windows was calculated. The beam-to-beam variation and day-to-day variation in the residual motion were calculated for both gating modalities. We found that the residual motion (95th percentile) was between 0.7 and 5.8 mm, 0.8 and 6.0 mm, and 0.9 and 6.2 mm for 20%, 30% and 40% duty cycle windows, respectively. Five of the eight patients showed less residual motion with amplitude-based gating than with phase-based gating. Large fluctuations (>300%) were seen in the residual motion between some beams. Overall, the mean beam-to-beam variation was 37% and 42% from the previous treatment beam for amplitudeand phase-based gating, respectively. The day-to-day variation was 29% and 34% from the previous day for amplitude-and phase-based gating, respectively. Although gating reduced the total tumour motion, the residual motion behaved unpredictably. Residual motion during treatment could exceed that which might have been considered in the treatment plan. Treatment margins that account for motion should be individualized and daily imaging should be performed to ensure that the residual motion is not exceeding the planned motion on a given day.
Although gating reduced the total tumour motion, the residual motion behaved unpredictably. Residual motion during treatment could exceed that which might have been considered in the treatment plan. Treatment margins that account for motion should be individualized and daily imaging should be performed to ensure that the residual motion is not exceeding the planned motion on a given day.
(Some figures in this article are in colour only in the electronic version)
Introduction
Many tumours in the abdomen and thorax have been observed to move during respiration (Weiss et al 1972 , Bryan et al 1984 , Suramo et al 1984 , Ross et al 1990 , Davies et al 1994 , Balter et al 1996 , Ekberg et al 1998 , Shimizu et al 1999 , Langen and Jones 2001 . Several respiratory motion compensation strategies have been proposed to minimize harmful effects (Ohara et al 1989 , Maruhashi et al 1992 , Kubo and Hill 1996 , Wong et al 1999 , Minohara et al 2000 , Schweikard et al 2000 , Shirato et al 2000a , Barnes et al 2001 , Keall et al 2001 , Harada et al 2002 , Kubo and Wang 2002 , Zhang et al 2003 , Berbeco et al 2004 , Mageras and Yorke 2004 . In approaches that gate the beam with no interruption of patient breathing, physiologically based surrogates of tumour location are used to trigger the therapeutic beam. Shirato et al (2000a) have reported a method for gating based on the three-dimensional location of a fiducial implanted near the tumour. Berbeco et al (2004) have suggested the use of fluoroscopic images for gating based exclusively on motion-enhanced tumour images, without implanted surrogates. Although these methods explicitly ensure that the location of the tumour is within the gating window, concerns of imaging dose, complexity or expense may discourage users. Several institutions and companies have developed techniques for respiratory gating based on the position of an external surrogate (or a collection of surrogates) placed on the thorax and/or abdomen. These systems do not require fluoroscopy during treatment. However, there is some uncertainty as to how well monitoring an external surface can predict internal tumour location as a function of time. Schweikard et al (2000) used infrared external markers and implanted radiopaque markers to periodically re-establish the internal/external correlation throughout a lengthy Cyberknife system (Accuray, Inc., Sunnyvale, CA) irradiation session. This may also suffer the same concerns, depending on the imaging frequency and total length of the treatment.
The question is: for regular linac based treatments, is an external surrogate alone sufficient for precise gated lung treatment? We use the measured patient data to examine this question. The residual tumour motion is calculated for several external gating duty cycles for the whole treatment. Beam-to-beam and day-to-day variations in the residual motion are also calculated. We comment on the reliability of external surrogate-based respiratory gating on these time scales.
Methods and materials

The patients
A total of eight lung patients were studied. The details of each patient are given in table 1. Patients 1-3 were brought to the NTT Hospital for the specific purpose of acquiring data for this study. Data were taken for only a single day for these patients. Patients 4-8 were treated Table 1 . Information about the patients studied. Patient 5 was treated twice, at the same site, with 2 months between treatments. The tumour site is indicated using the common anatomical notation for lung segmentation: S1-3 is upper lobe, S4-5 is middle lobe and S6-10 is lower lobe. with 40-48 Gy in four to eight fractions. This analysis only includes patients with marker motion greater than 1 cm peak-to-peak. Patient 5 was treated twice, 2 months apart. Since the same site was treated and no isocentre shift was made, we used both sets of data in the evaluation, under the same patient name. Some beams/day were excluded because the patient shifted during treatment.
External and internal gating systems
The Radiation Oncology Clinic at the Nippon Telegraph and Telephone Corporation (NTT) Hospital in Sapporo, Japan, is equipped with a Mitsubishi real-time radiation therapy (RTRT) system (Shirato et al 2000a) . Patients with abdominal and thoracic tumours, treated with this system, typically have two to four 1.5 mm diameter gold ball bearings (bb's) implanted in or near the tumour (Shirato et al 2003) . These markers are tracked in real time with diagnostic x-ray fluoroscopy, and the treatment beam turned on when a marker is within a predetermined 3D window (Shirato et al 2000a) . The routine practice is to use a 3D window that is ±2.5 mm from the planned position in each direction (LR, SI and AP) . The system at the NTT Hospital differs from the usual RTRT system in that there are only two pairs of x-ray tubes and imagers rather than four. Therefore, at some gantry angles, one of the x-ray views may be blocked. To facilitate gating at these angles, an external surrogate gating system was installed and integrated with the RTRT system by Mitsubishi. The AZ-733V external respiratory gating system (Anzai Medical, Tokyo, Japan) uses a laser to monitor the movement of the patient's abdominal surface. The housing, which contains both the source and the detector, is attached to the treatment couch by an extendable arm and the beam is placed orthogonal to the patient's skin surface. The device calculates the change in the surface amplitude by measuring the relative position of the reflected light. The result is a 1D relative measurement of the abdominal surface. For the purposes of this study, the external surface was monitored when neither of the x-ray views was obscured. The signal from the surface monitor is synchronized with the signal from the fluoroscopic unit so that the log files contain the three-dimensional marker position and the external surface position at every time point. The rate of data acquisition for this entire system is 30 frames s -1 . Note that the fluoroscopic and laser measurements are taken even when the treatment beam is gated off. Data are acquired throughout each treatment, so we were able to obtain large amounts of internal/external correlated data.
Patient setup
In the CT simulation session, a scan is taken with the patient's breath held at the end of exhale. At each treatment session, patients are initially set up to skin marks using in-room lasers. Short fluoroscopic imaging sessions are performed to determine the position of the markers at the end of exhale phase. The 3D marker position is compared to the planned position. The RTRT system then calculates the appropriate couch shift (performed by the therapist) to bring the target to isocentre. The physician monitors the fluoroscopy to verify that the markers are properly tracked and are within the internal gating window at the end of exhale. A complete description of the treatment procedure has been written by Shirato et al (2000) .
The accuracy of externally gated treatment can be broken up into two factors: (1) daily variation of tumour home position (e.g. end-of-exhale tumour position) and (2) residual motion of the tumour within the external gating window. In a gated treatment procedure, the patient is set up such that, at the end of exhale, the tumour is at the reference home position. Therefore, the setup is not only patient positioning but also tumour positioning. If the patient is accurately positioned, based on the end-of-exhale tumour location before each fraction of treatment, then day-to-day error is minimized. During data taking for this study, fluoroscopy was taken prior to each treatment to ensure that the implanted markers were at the planned positions at the end of exhale. This method allows us to set aside the errors associated with patient setup and inter-fractional tumour motion and focus on those uncertainties arising from internal residual tumour motion within the external gating window throughout the treatment.
Data analysis
The data acquired by both the internal and external monitoring systems indicate a 'position' at each time step. For the external monitoring system, the position is the distance from the abdominal surface to the laser housing. In the internal monitoring system, the position of the tracked marker is calculated in isocentre coordinates. To calculate the phase of the external signal for each time point, a retrospective algorithm is employed (Neicu et al 2003) . The end of inhale is assigned phase angle 0/2π degrees and the phase angle of exhale is generally around π , depending on the shape of the breathing waveform.
Residual tumour motion is assessed for two gating strategies: amplitude-based gating and phase-based gating. It has been noted in the literature that there are potential problems with each of these methodologies, which may be tied to issues of correlation. Each method can be problematic if a patient's depth of breathing is inconsistent. A patient's breathing waveform may experience a baseline drift, potentially causing the beam to turn on during an unintended interval (Mageras and Yorke 2004) . In phase-based gating, shallow exhales will trigger a beam at different amplitudes than deeper exhales (see figure 1) .
Amplitude-based gating.
In this study, we have chosen the gating amplitude window to encompass patient's end of exhalation. The gate is open when the external amplitude falls below a predefined level. Gating windows were chosen for each beam such that the duty cycle was 20%, 30% or 40%, respectively. The gating windows were chosen such that the lower part of the gate was always less than the minimum of the amplitude. The residual motion is defined to be the motion of internal markers during the open external gating window. For each beam, there will be a 3D collection of data points representing the positions of the internal marker when the external amplitude was within the gating window. The median of these points (the median gated position) is the reference point from which r internal is calculated. r internal is the magnitude of the 3D distance between each gated data point and the median gated position. A representative plot of r internal for amplitude-based gating is shown in figure 2(a) . 
Phase-based gating.
A similar analysis is performed for phase-based gating. The phase for the gating window is found by an exhaustive search of all phase angle windows in 0.1 radian increments. The gates are selected which result in the lowest residual motion for 20%, 30% and 40% duty cycle. This represents the best possible phase gating region for each duty cycle. These gating regions tended to be near the end of exhale. The residual motion is defined to be the collection of internal data points corresponding to the external gating window. The median of these points (the median gated position) is the reference point from which r internal is calculated. A representative plot of r internal for phase-based gating is shown in figure 2(b) . Table 2 . The mean and 95th percentile residual motion at 20%, 30% and 40% for amplitude-and phase-based gating (d.c. = duty cycle, A = amplitude-based gating, P = phase-based gating and n = negligible motion).
Mean residual motion (mm)
95th percentile residual motion (mm) 
Results and discussion
Range of residual motion
The 95th percentile of residual motion in a 40% duty cycle window is chosen as the metric by which we judge the efficacy of gating. This makes our discussion of the results easier to present. Inspecting table 2, five of the patients (1, 4, 5, 6 and 8) show reduced residual motion with amplitude gating versus phase-based gating. The other patients show the contrary, although each to varying degrees. Overall, in this group of patients, neither amplitudebased gating nor phase-based gating is definitively better than the other. Three patients (4, 5 and 7) have small residual motion (<2.5 mm) for both gating modalities, even at 40% duty cycle. Patient 2 also shows similar results for both modalities but with slightly more motion. Patient 3 has significantly less residual motion with phase-based gating (<2 mm). The residual motion for each patient does not appear to be well correlated with the size of the total motion (un-gated). Although patient 1 has the largest un-gated motion, patients 6 and 8 have more residual motion for both modalities and patients 2 and 3 have more for amplitude-based gating. Total motion does not appear to be a good predictor of the size of the residual motion. Only patient 3 exhibits significant motion in all three directions. The 95th percentile residual motion histograms for the LR, SI and AP directions are shown in figure 3 . The tail in the posterior direction in the amplitude gating, for patient 3, gives rise to the larger residual motion for this modality. The external amplitude as a function of the internal motion in the AP direction is shown in figure 4(a) . Amplitude gating accepts a wider range of data in the AP direction than phase-based gating. External amplitude versus external phase is shown in figure 4(b) . The phase-based gating prefers points on the exhalation side of the minimum (i.e. left of the minimum). Given that the phase-based gating leads to less residual motion for this patient, figure 4(b) implies that external phase correlates better with internal motion than external amplitude. This does not appear to be true for all of the other patients.
Patients 1, 6 and 8 have significantly less residual motion with amplitude-based gating compared to phase-based gating (38%, 29% and 32% less, respectively). Plots of the external amplitude as a function of the internal motion in the SI direction for patient 6 are shown in figure 5. To better see in which phase direction the gated phase points are, external amplitude is plotted as a function of external phase for all three patients (1, 6 and 8) in figures 6(a)-(c).
The phase-gated points extend beyond the amplitude-gated points in both inhale and exhale directions. The large width of the collection of data points near the minimum leads to phasebased gated points beyond the amplitude gate. The width is a measure of the reproducibility of the phase/amplitude relationship. This relationship can be made more reproducible through breath coaching (Mageras et al 2001 , Kini et al 2003 , Neicu et al 2004 . However, there is no evidence, yet, that breath coaching has a significant effect on the reproducibility of the tumour motion itself. Patients with seriously compromised pulmonary function can have inconsistent breathing. We have noticed that these patients are the most difficult to coach. It is a catch-22: the very patients for whom breath coaching may have the most benefit are those who cannot be The external amplitude as a function of the external phase for patient 3. The phase-gated points are blue, the amplitude-gated points are red and points representing the union of the two are green. A 40% duty cycle is used for both of these plots for both phase and amplitude gating. coached. In the absence of breath coaching, amplitude-based gating is best for the inconsistent breathers (patients 1, 6 and 8) in our group. Even so, the residual motion for these patients is still among the highest.
Patient 2 Patient 4
Patient 5 Patient 7 Figure 7 . The external amplitude is plotted as a function of the external phase for patients 2, 4, 5 and 7. The phase-gated points are blue, the amplitude-gated points are red and points representing the union of the two are green. A duty cycle of 40% was used for all of these plots.
Patients 2, 4, 5 and 7 show the least difference in residual motion between amplitudeand phase-based gating. Patients 2 and 7 have 13% and 11% less motion, respectively, with phase-based gating versus amplitude-based gating. Patients 4 and 5 have 6% and 18% less residual motion, respectively, with amplitude-based gating versus phase-based gating. Plots of the external amplitude as a function of external phase are shown in figures 7(a)-(d). Note that even though the resulting residual motions are similar, there are still portions of the gated points that are different. Patients 2 and 5 show a preference for phases on the exhale side of the minimum, like patient 3. However, the preference is not pronounced enough to give the same residual motion effect. Patients 4 and 7 show the opposite preference. No definitive phase/amplitude relationship can be deduced from these contradictory results. The correlation between internal motion and external phase and external amplitude varies across the population of patients studied. There is no clear universal preference for one gating modality over the other.
Variation in residual motion
We studied the variability of the residual motion, beam-to-beam and day-to-day, throughout the course of treatment. For this part of the study, the first three patients were not analysed. The residual motion as a function of beam and as a function of day for each patient is shown in figures 8 and 9 for amplitude-and phase-based gating, respectively. Large changes in the residual motion are possible from beam to beam. Day 3 for patient 6 goes from beam 10 to beam 14. When amplitude gating, there is an increase of 327% between beams 10 and 11 and then a gradual decrease through the rest of that day's beams. We found that, among all the patients, the mean change from beam to beam was 37% for amplitude gating and 42% for phase-based gating. In general, each patient showed similar beam-to-beam changes for both gating modalities.
The residual motion was averaged over each day to study the daily change. The average daily residual motion change from the previous day was 25%, 30%, 17%, 48% and 9% for amplitude-based gating and 31%, 35%, 26%, 48% and 43% for patients 4-8, respectively. The average over all of the patients is 29% and 34% for amplitude-and phase-based gating, respectively. Patient 6 shows a general trend towards increasing residual motion as the treatment progresses for both gating modalities. Patients 5 and 7 show a decrease in residual motion through the course of treatment. The rest of the patients do not appear to have a noticeable trend in either direction for both gating modalities. It is unclear what factors could lead to a systematic change in the residual motion over several days.
The large fluctuations in residual motion that occur intra-fractionally and inter-fractionally are cause for concern. If one were to use an external gating system without any daily imaging, there would be no way to detect change in the residual tumour motion. Even at the same external duty cycle, the tumour may exhibit more or less motion on a given day. Treatment margins deduced from a simulation session before the course of treatment is begun may not be appropriate for each fraction. The use of inappropriate margins could lead to under-dosing of the target and/or over-dosing of the normal tissue. The dosimetric effect of the changing residual motion has not yet been studied. We highly recommend daily imaging of the patient to ensure that the tumour is moving as expected during treatment.
Conclusion
Residual tumour motion during external surrogate respiratory gating for both amplitude-and phase-based gating has been studied in eight patients. The data were taken over the complete course of treatment for five lung cancer patients and on a single day for three lung cancer patients. Neither gating modality proved to be definitively superior from a residual motion perspective. The significant reduction in residual motion for three of the patients using amplitude-based gating appears to be due to the irreproducibility of the breathing waveform. This will be the basis of future studies.
Overall, every patient exhibited significant reduction of the tumour motion for external gating. The variation in residual motion from patient to patient indicates that margins associated with residual tumour motion should be prescribed on a case-by-case basis. A single margin will not be appropriate for all gating patients. The tumour motion should be observed in a simulation session and an appropriate, individualized, gating window assigned before the beginning of treatment. However, our results show that the gating window may need to be adjusted during the course of treatment to account for changes in the residual motion.
The beam-to-beam and day-to-day variations indicate that, for some patients, residual motion can have pronounced changes during a course of treatment. This will be most problematic in treatments consisting of only a few fractions, where an anomalously large residual motion during one beam/day will have a greater overall effect than during a longer treatment. It would be best to use some method of online verification or real-time marker/tumour tracking in order to confidently gate treatment.
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